Table 1.
Demographic characteristics, laboratory values and clinical features of PV patients at time of first JAK2V617F determination, n = 105.
| Men, no. (%) | 52 (49.5) |
| Women no. (%) | 53 (50.4) |
| Age: mean ± s.d., median age (range), years | 60.0 ± 12.0, 60.0 (35.0–88.0) |
| Median time between diagnosis and JAK2 analysis in years (range) | 4.6 (0.0–34.0) |
| Median duration follow-up after JAK2 analysis in years (range) | 1.0 (0.1–3.6) |
| HCT (%) mean ± s.d., median (range) | 42.3 ± 4.3, 42.5 (25.4–55.9) |
| WBC (× 109/L) mean ± s.d., median (range) | 11.4 ± 8.4, 9.0 (2.9–65.6) |
| PLT(× 109/L) mean ± s.d., median (range) | 426.2 ± 245.6, 385.0 (59.2–1090.0) |
| Splenomegaly, no. (%)1 | 42 (40.4) |
| Spleen size, cm below the left costal margin, mid-clavicular line, no. (%) | |
| 0 cm | 62 (59.0) |
| >0–3 cm | 26 (24.8) |
| 4–9 cm | 9 (8.6) |
| >9 cm | 7 (6.7) |
| Mean ± s.d., median (range) | 2 ± 4, 0 (0–13) |
| Thromboses, no. (%) | 27 (25.7) |
| Single arterial thrombosis | 16 (15.2) |
| Single venous thrombosis | 9 (8.6) |
| Both arterial and venous thromboses | 2 (1.9) |
| Myelofibrosis, no. (%) | 64 (61.0) |
| Grade 1 | 27 (25.7) |
| Grade 2 | 19 (18.1) |
| Grade 3 | 14 (13.4) |
| Grade 4 | 4 (3.8) |